echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Investment and financing in the field of medicine and biology are active, and enterprise innovation will usher in accelerated development

    Investment and financing in the field of medicine and biology are active, and enterprise innovation will usher in accelerated development

    • Last Update: 2022-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    【Pharmaceutical Network Market Analysis】On December 16, ABio announced that it has completed a $15 million seed round of financing
    .
    The round was co-led by Sequoia China Seed Fund and Eight Roads in collaboration with F-Prime Capital
    .
    The funds will be used to build and serve as a platform for innovation discovery and to advance the company's current lead drug candidates for the toughest
    cancers.
    It is understood that EverBio is a privately held biotechnology company that develops new drugs targeting chemically modified processing enzymes, and has expertise in signal transduction, gene expression regulation, cancer biology and drug discovery
    .
    On December 5, Qingke Biotech received 400 million yuan in financing
    .
    This round of financing is mainly used for the R&D investment, technology platform upgrade and talent team expansion of Qingke Biogene Factory, as well as the layout of promoting international operation to create an intelligent and automated production platform
    that meets global standards.
    Prior to this, Guosen Pharmaceutical also announced the completion of a series B+ financing of nearly 100 million yuan, after the completion of this round of financing, the company will continue to focus on and deepen the clinical research of innovative drugs in cutting-edge pipelines, deepen business and technology, and continue to highlight the advantages
    in the field of cell and gene therapy (CGT).
    According to the data, Guosen Pharma focuses on innovative drugs, cell and gene therapy clinical CRO services, and has become the head clinical CRO
    in the field of cell and gene therapy (CGT) in China.
    In addition to the above companies, since 2022, a large number of pharmaceutical companies have also obtained financing
    .
    According to data, since November, the net purchase of A-share financing has reached more than
    28 billion yuan.
    As of November 21, the financing balance of the two cities was 1.
    47 trillion yuan
    .
    In terms of industries, the five major industries such as medicine and biology, power equipment, computers, electronics, and basic chemicals have financed net purchases of more than 2 billion yuan
    since November.
    Among them, the net purchase amount of pharmaceutical and biological financing was nearly 10.
    4 billion yuan, making it an industry
    with a high amount of financing funds.
    Since December, pharmaceutical and biological financing has also been very active
    .
    Statistics show that of the 28 primary industries to which Shenwan belongs, a total of 12 industry sectors received net purchases of financing on December 13, and 5 of them had a net purchase amount of more than 100 million yuan
    .
    Among them, the pharmaceutical and biological industry ranked first in net purchases of financing, with a net purchase of 1.
    107 billion yuan
    on the day.
    On December 5, 21 industry sectors received net buying
    .
    Among them, the pharmaceutical and biological industry also led the net purchase of financing, with a net purchase of nearly 1.
    2 billion yuan on the day, reaching 1.
    183 billion yuan
    .
    Industry analysts believe that the support of many favorable policies and the entry of a large amount of capital are accelerating the development of high-quality innovation in the pharmaceutical and biological industry
    .
    Affected by this, the pharmaceutical and biological sector began to rebound strongly, and the financing funds increased significantly
    .
    For example, last month, the pharmaceutical biology index rose by more than 6%.

    During this period, more than ninety percent of pharmaceutical stocks recorded a rise, among which Teyi Pharmaceutical, Wonder Pharmaceutical, Zhongsheng Pharmaceutical, Hendi Pharmaceutical, Tailong Pharmaceutical, etc.
    rose by more than 50%, becoming popular stocks
    sought after by market funds.
    In the context of the bottom of the medical insurance centralized procurement policy and the gradual elimination of the influencing factors that suppress the valuation of the pharmaceutical industry, analysts pointed out that the upward performance and valuation repair will bring continuous upward momentum
    to the pharmaceutical and biological industry.
    In the future, a large number of internationally competitive Chinese biomedical innovation enterprises are expected to emerge, helping China's pharmaceutical bio-innovation industry to accelerate its high-quality development
    .
    Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
    to anyone.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.